Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 5/2007

01-12-2007 | Introduction

Introduction: severe sepsis and drotrecogin alfa (activated)

Authors: Antonio Artigas, Claude D Martin

Published in: Critical Care | Special Issue 5/2007

Login to get access

Excerpt

Despite continuing advances in intensive care medicine, severe sepsis and septic shock are currently among the most common causes of morbidity and mortality in intensive care. Moreover, the incidence of severe sepsis and septic shock has increased with ageing of the population over the past decade [1‐3]. The Surviving Sepsis Campaign advocates early identification and intervention worldwide to improve overall management of sepsis and to reduce sepsis-related death [4, 5]. …
Literature
1.
Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome and associated costs of care. Crit Care Med. 2001, 29: 1303-1310. 10.1097/00003246-200107000-00002.CrossRefPubMed
2.
Martin GS, Mennino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003, 348: 1546-1554. 10.1056/NEJMoa022139.CrossRefPubMed
3.
Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, Sicignano A, Palazzo M, Moreno R, Boulmé R, Lepage E, et al: Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med. 2002, 28: 108-121. 10.1007/s00134-001-1143-z.CrossRefPubMed
4.
Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Perterson E, Tomlanovich M, Early Goal-Directed Therapy Collaborative Group: Early goal directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001, 345: 1368-1377. 10.1056/NEJMoa010307.CrossRefPubMed
5.
Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Surviving Sepsis Campaign Management Guidelines Committee, et al: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004, 32: 858-873. 10.1097/01.CCM.0000117317.18092.E4.CrossRefPubMed
6.
7.
Levi M, van der Poll T: Recombinant human activated protein C: current insights into its mechanism of action. Crit Care. 2007, 11 (suppl 5): S3-10.1186/cc6154.PubMedCentralCrossRefPubMed
8.
Nick JA, Coldren C, Geraci MW, Poch KR, Fouty BW, O'Brien J, Gruber M, Zarini S, Murphy RC, Kuhn K, et al: Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood. 2004, 104: 3878-3885. 10.1182/blood-2004-06-2140.CrossRefPubMed
9.
Feistritzer C, Riewald M: Endothelial barrier protection by activated protein C through PAR-1 dependent sphingosine-1-phosphate receptor-1 crosses activation. Blood. 2005, 105: 3178-3184. 10.1182/blood-2004-10-3985.CrossRefPubMed
10.
Vangerow B, Shorr AF, Wyncoll D, Janes J, Nelson DR, Reinhart K: The protein C pathway: implications for the design of the RESPOND study. Crit Care. 2007, 11 (suppl 5): S4-10.1186/cc6155.PubMedCentralCrossRefPubMed
11.
12.
13.
Metadata
Title
Introduction: severe sepsis and drotrecogin alfa (activated)
Authors
Antonio Artigas
Claude D Martin
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Critical Care / Issue Special Issue 5/2007
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc6180

Other articles of this Special Issue 5/2007

Critical Care 5/2007 Go to the issue

Review

Practical aspects of treatment with drotrecogin alfa (activated)

Review

The protein C pathway: implications for the design of the RESPOND study

Review

Recombinant human activated protein C: current insights into its mechanism of action

Review

Clinical trials in severe sepsis with drotrecogin alfa (activated)

Review

Diagnosis and treatment of severe sepsis

Review

The safety profile of drotrecogin alfa (activated)